Key Takeaways Stem cell therapy for anoxic brain injury is still experimental, and no study has compared early with late treatment in people. Most natural recovery after cardiac arrest occurs in the first three months, a 2017 study of 141 survivors found. Cooling newborns within six hours reduces death and
Key Takeaways A Japanese health ministry panel backed full approval of Stemirac, a bone marrow cell therapy, on 15 October 2026. Reported data compared 73 treated patients with 66 untreated patients, and 40 treated patients improved in motor function. Treated patients received more rehabilitation, so it’s hard to isolate the
Key Takeaways Stem cell therapy for cerebral palsy is still experimental and is not established standard care. A 2021 randomized trial of 72 children reported higher motor scores 12 months after cord tissue cells than after a pretend procedure. Two 2025 reviews found average gains of about 1 to 1.5
Key Takeaways Stem cell therapies for kidney disease are still experimental, and a 2025 review found lower inflammation markers in animals but no clear change in people. That review pooled 49 animal studies and only three small human trials involving 86 people. Standard care, such as blood pressure control, remains
Key Takeaways Doctors in Shanghai transplanted stem cell derived islet tissue into a man with type 2 diabetes in 2019. The patient stopped using insulin injections within eleven weeks and stayed insulin-free for years afterward. A separate 2026 study used the same method in three patients with type 1 diabetes,
Key Takeaways Most trials do not measure meaningful change until at least one month, with pain relief typically building gradually through 3 to 6 months. By 12 months, trial data show improvements in both pain and function, with dose and cell source affecting how strong and how long-lasting that benefit
Key Takeaways A 2024 network meta-analysis of 48 studies ranked PRP highest for knee osteoarthritis pain and function, followed by a bone marrow cell-based option, then hyaluronic acid (HA). The cell-based option’s ranking rests on far fewer studies (2.5% of the pooled evidence) than HA’s ranking (nearly 41%), so that
Key Takeaways Umbilical cord MSCs for stroke are being studied as a possible add-on to standard rehabilitation, not a replacement for it. A 2025 randomized trial in 32 patients found IV delivery led to significant improvements at 6 months, with both IV and intrathecal groups improving by 12 months. A
Key Takeaways Stem cells for disc degeneration can be delivered in two ways: intradiscal injection straight into the disc, or IV infusion through a vein. A 2014 mouse study found intradiscal injection preserved disc height better, while IV delivery still boosted some tissue-repair markers without that structural effect. Cyrona Cell
Key Takeaways Chronic, low-grade inflammation and insulin resistance drive each other in a two-way loop that starts largely in visceral fat. Mesenchymal stem cells are being studied for their ability to calm this inflammation and support insulin sensitivity, not to replace diet, exercise, or medication. A 2022 randomized trial found
